Exelixis Analyst Ratings
BenzingaApr 11 20:54
Barclays Downgrades Exelixis (EXEL) to a Hold
TipRanksApr 11 15:05
J.P. Morgan Securities: Reiterates the Exelixis (EXEL.US) rating and adjusted from superior to superior market rating, with a target price of $27.00.
Zhitong FinanceApr 10 23:10
Exelixis Analyst Ratings
BenzingaApr 10 23:07
JMP Securities Reiterates Market Outperform on Exelixis, Maintains $27 Price Target
BenzingaApr 10 23:08
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
TipRanksApr 10 12:25
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
TipRanksApr 9 10:10
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
TipRanksMar 21 18:20
Truist Financial Keeps Their Buy Rating on Exelixis (EXEL)
TipRanksFeb 26 20:17
Maintaining Buy Rating on Exelixis Amid Patent Litigation and Strong Growth Prospects
TipRanksFeb 23 20:48
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
TipRanksFeb 12 21:20
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Envista Holdings (NVST)
TipRanksFeb 12 10:10
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL)
TipRanksFeb 8 20:50
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)
TipRanksFeb 8 13:30
Exelixis Analyst Ratings
BenzingaFeb 8 01:19
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating
MT NewswiresFeb 7 21:22
Piper Sandler Remains a Buy on Exelixis (EXEL)
TipRanksFeb 7 21:18
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
TipRanksFeb 7 20:32
Exelixis Receives Buy Rating From David Lebovitz on Strong Financials and Growth Prospects
TipRanksFeb 7 19:55
Buy Rating on Exelixis: Growth Prospects Amid Patent Rulings and Pipeline Developments
TipRanksFeb 7 18:31
No Data
No Data